Patrick Campbell

Philip Mease, MD, Director of Rheumatology Research at Swedish Rheumatology Research Group, reflects upon new data and discusses where he sees guselkumab fitting into a PsA patient's current treatment plan.

A new study from ACR 2019 found tocilizumab outperformed rituximab in rheumatoid arthritis patients with low B-cell levels.

Daniel Clauw, MD, of the University of Michigan, discusses how the diagnosis of a rheumatic condition can impact the mental health of patients.

Jeffrey Curtis, MD, discusses how the Vectra test can be a useful tool for rheumatologists at ACR 2019.

An analysis of more than 7000 patients presented at ACR 2019 found there was no significant differences in safety or efficacy of biologic DMARDs based on the age of RA onset.

Elaine Husni, MD, discusses how she goes about choosing which therapy is most appropriate for a patient with psoriatic arthritis.

Daniel Clauw, MD, of the University of Michigan, discusses the impact public perception has had on pain management practices for patients with rheumatic diseases and chronic pain.

Using the largest SLE birth cohort ever established, investigators determined children exposed to non-TNF inhibitors in utero were at a low risk of serious infection.

A 19-year analysis presented at ACR 2019 has found opioid use disorder hospitalizations among some rheumatic diseases have increased more than 30-fold since 1998.

Jeffrey Curtis, MD, discusses the results of a study he led examining the safety of the zoster vaccine in immunocompromised populations, specifically patienta with rheumatic diseases receiving TNF inhibitors.

Patients with lupus were at an increased risk of 30-day all-cause mortality following coronary revascularization when compared to patients with diabetes mellitus and the general population.

A new study presented at ACR 2019 is debunking the notion that use of ultrasound to guide treatment in early rheumatoid arthritis provides added benefit over conventional treatment strategies.

A new study has found use of methotrexate could reduce joint damage progression and facilitate bone remodeling in patients with hand osteoarthritis.

A new study presented at ACR 2019 has found spending on bDMARDs nearly doubled between 2012 and 2016, with post-market drug price changes driving most of the increase.

New 2020 osteoarthritis guidelines, developed by the American College of Rheumatology and the Arthritis Foundation, were previewed during ACR 2019.

American College of Rheumatology officials are offering clinicians an early look at some of the recommendations in the drafted gout guidelines the ACR is set to debut in 2020.

A study presented at CCR West found that tocilizumab displayed better biologic persistence compared with other biologics in patients with rheumatoid arthritis who previously received 1 or more other biologics.

Novartis announced the ongoing Phase 3 PREVENT trial examining use of secukinumab in patients with non-radiographic axial spondyloarthritis has met its primary endpoint of ASAS40.

Sheetal Desai, MD, AWARE investigator and assistant clinical professor of medicine at UC Irvine, discusses full 52-week results of study comparing 2 popular rheumatoid arthritis patients and what the observed safety profile means from a patient-centered perspective.

Aaron Broadwell, MD, rheumatologist and AWARE investigator, discusses his interpretation of the full 52-week results of the trial, which examined golimumab and infliximab in patients with rheumatoid arthritis in a real-world setting.

A post hoc analysis of the OPAL Beyond and OPAL Broaden studies found tofacitinib improved skin-related symptoms and health-related quality of life in psoriatic arthritis patients with an inadequate response to csDMARDs or TNFi treatment.

A study examining a gene expression classifier from Scipher Medicine called PrismRA found the system could be used to identify at least half of the non-responders with at least 90% accuracy.

A 12-week phase 2 study comparing filgotinib to placebo found the oral, selective JAK1-inhibitor could be an effective treatment for ankylosing spondylitis.

Theresa Lawrence Ford, MD, CEO and medical director of North Georgia Rheumatology Group and board member of the Association of Women in Rheumatology, gives her opinion on the current state of burnout among rheumatologists.

Sheetal Desai, MD, a rheumatologist and investigator of the ongoing AWARE trial, discusses her clinical takeaways from the 52-week results and the importance of real-world evidence.

AWARE Trial investigator Aaron Broadwell, MD, discusses what new data was presented during CCR West and how it differed from a previously presented interim analysis.

Maria Greenwald, MD, rheumatologist, discusses what she sees as a glaring issue in medicine—the lack of knowledge among many physicians as to how much treatments will cost and how to mitigate the impact of those costs.

A study from CCR West 2019 has found that tofacitinib can cut the time to clinically significant pain improvement in psoriatic arthritis patients by nearly half the time when compared to placebo therapy.

Maria Greenwald, MD, rheumatologist with Desert Medical Advances, discusses the results of a study she conducted that sought to identify the most effective ways a physician can advise a patient on how to save money on treatments.

While conferences and annual meetings are often the place clinicians are exposed to new data, there are often niche areas where they seek further guidance or information. Janet Pope, MD, discusses where she would like to see more research dedicated.